The influence of sialidase on the management renal anemia therapy in CKD patients

The influence of sialidase on the management renal anemia therapy in CKD patients - SMART-CKD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020907

Enrollment

1400

Registered

2016-05-01

Start date

2016-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic kidney disease patients Age over 20 to 90 years

Exclusion criteria

Exclusion criteria: Infectious disease neoplasm bleeding complications dementia

Design outcomes

Primary

Measure	Time frame
1.Association of slilidase activity with estimated glomerular filtration ratio 2.Association of slilidase activity with hemoglobin level 3.Association of slilidase activity with usage and dosage of erythropoiesis stimulatory agent	—

Countries

Japan

Contacts

Public ContactNobuhiko Joki

Toho University Ohashi Medical Center Division of Nephrology

jokinobuhiko@gmail.com+81-3-3468-1251

Outcome results